Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2014-10-31 Regulatory Filings
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 99% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a 'stock buyback program' announced previously. This action directly relates to the company acquiring its own shares. The filing category 'Transaction in Own Shares (POS)' is defined as the report of the company buying back or selling its own shares. Although the text mentions reading the full announcement in PDF format (suggesting RPA/RNS), the core content is the transaction itself, making POS the most specific classification for the subject matter, especially given the very short length which often accompanies these specific transaction disclosures.
2014-10-31 English
Transaction in Own Shares 2014
Transaction in Own Shares Classification · 99% confidence The document text, dated October 31, 2014, details the specific number of B-shares repurchased by Novozymes under an ongoing share buyback program (aktietilbagekøbsprogram) initiated in February 2014, referencing a previous company announcement (selskabsmeddelelse nr. 17, 2014) and compliance with the 'Safe Harbour Regulation'. It provides a detailed table of daily transactions and updates the total number of treasury shares held. This content directly relates to the company managing its own stock capital through repurchase activities. This aligns precisely with the definition for 'Transaction in Own Shares' (POS).
2014-10-31 English
Transaction in Own Shares 2014
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a 'stock buyback program' announced previously. This action directly relates to the company acquiring its own shares. The filing category 'Transaction in Own Shares' (POS) is defined as 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although the text mentions reading the full announcement in PDF, the core content is the transaction update itself, making POS the most specific fit over the general RPA/RNS fallback, given the very short length and direct reporting of the buyback activity.
2014-10-24 English
Transaction in Own Shares 2014
Transaction in Own Shares Classification · 99% confidence The document details the accumulated number of shares purchased by Novozymes under its stock buyback program, including specific daily transaction tables and references to the total program limit (DKK 2 billion). This activity directly relates to the company managing its own outstanding shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase programs. The document length is short (3533 chars) and it is a direct announcement of the transaction details, not an announcement of a larger report.
2014-10-24 English
Transaction in Own Shares 2014
Transaction in Own Shares Classification · 99% confidence The document text explicitly details transactions made by Novozymes under an 'aktietilbagekøbsprogram' (share buyback program). It reports the number of shares bought, the total transaction value, and the resulting number of own shares held. This activity directly relates to the company managing its own stock capital. The most specific category for reporting the company buying back or selling its own shares is 'Transaction in Own Shares' (POS). Although it involves capital, it is specifically about share repurchase, not general financing (CAP) or a general share issue (SHA). The document is a direct announcement of these transactions, not an announcement of a report (RPA).
2014-10-17 English
Regulatory Filings 2014
Regulatory Filings Classification · 99% confidence The document text is very short (271 characters) and explicitly states that Novozymes bought back a specific number of shares under a previously announced share repurchase program ('aktietilbagekøbsprogram'). The final sentence, 'Læs hele meddelelsen i pdf format' (Read the full announcement in pdf format), strongly suggests this is a brief notification about a transaction rather than the full regulatory filing detailing the transaction. This aligns best with the 'Transaction in Own Shares' category (POS), which covers share repurchase reports. Although it is a short announcement, the content is highly specific to share transactions, making POS a better fit than the general RPA or RNS.
2014-10-17 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.